keyword
MENU ▼
Read by QxMD icon Read
search

Radioiodine treatment

keyword
https://www.readbyqxmd.com/read/27909769/evaluation-of-131-i-scintigraphy-and-stimulated-thyroglobulin-levels-in-the-follow-up-of-patients-with-dtc-a-retrospective-analysis-of-1420-patients
#1
Jose Manuel Gonzalez Carvalho, Dennis Görlich, Otmar Schober, Christian Wenning, Burkhard Riemann, Frederik Anton Verburg, Alexis Vrachimis
AIM: To study the clinical yield of diagnostic whole body (131)I scintigraphy (DxWBS) in the follow-up of differentiated thyroid carcinoma (DTC) patients in relation to stimulated thyroglobulin (sTg) in the initial post-ablation setting, as well as in the setting of repeated monitoring in course of further DTC follow-up. METHODS: Data of 1420 thyroidectomized and radioiodine remnant-ablated DTC patients following a well-defined therapy and standardized follow-up protocol were evaluated...
December 1, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27908147/strategies-for-ct-tissue-segmentation-for-monte-carlo-calculations-in-nuclear-medicine-dosimetry
#2
P E N Braad, T Andersen, S B Hansen, P F Høilund-Carlsen
PURPOSE: CT images are used for patient specific Monte Carlo treatment planning in radionuclide therapy. The authors investigated the impact of tissue classification, CT image segmentation, and CT errors on Monte Carlo calculated absorbed dose estimates in nuclear medicine. METHODS: CT errors as a function of patient size, CT reconstruction, and tube current modulation methods were assessed in a phantom experiment on a clinical CT system. The impact of tissue segmentation methods and CT number variations on EGSnrc Monte Carlo calculated absorbed dose distributions was assessed for (99m)Tc and (131)I in the ICRP/ICRU male phantom and in a patient PET/CT-scanned with (124)I prior to radioiodine therapy...
December 2016: Medical Physics
https://www.readbyqxmd.com/read/27902601/time-course-of-graves-orbitopathy-after-total-thyroidectomy-and-radioiodine-therapy-for-thyroid-cancer
#3
Camille Louvet, Annamaria De Bellis, Bruno Pereira, Claire Bournaud, Antony Kelly, Salwan Maqdasy, Beatrice Roche, Francoise Desbiez, Francoise Borson-Chazot, Igor Tauveron, Marie Batisse-Lignier
The risk of cancer is relatively higher in Graves' patients presenting simultaneously with thyroid nodules. Radioiodine (RAI) therapy recommended in high-risk differentiated thyroid carcinoma may be associated with worsening of a pre-existing Graves' orbitopathy (GO) or developing a new onset. The impact of RAI therapy in patients with differentiated thyroid cancer on the course of a pre-exisiting GO has not been specifically investigated.The aim of this study is to assess the influence of RAI treatment administered for differentiated thyroid cancer on the course of a pre-existing GO...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27893690/prognosis-of-papillary-thyroid-carcinoma-in-elderly-patients-after-thyroid-resection-a-retrospective-cohort-analysis
#4
Nathalie Chereau, Christophe Trésallet, Severine Noullet, Gaelle Godiris-Petit, Frederique Tissier, Laurence Leenhardt, Fabrice Menegaux
The size of the elderly population and the incidence of papillary thyroid carcinoma (PTC) in this group appear to be rapidly increasing, although published information based on more detailed older age groupings are lacking.This study aimed to determine the clinical features and outcomes of elderly patients in PTC.All consecutive patients who received surgery for PTC in our Department from 1978 to 2014 were included. We compared 3 patient groups: young (<65 years), older (65-75 years), and very old patients (>75 years)...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27884196/palliative-treatment-of-pelvic-bone-tumors-using-radioiodine-125-i-brachytherapy
#5
Chongren Wang, Zhengqi Chen, Wei Sun, Yisilamu Yasin, Chuanyin Zhang, Xiaojun Ma, Jian Chen, Jiakang Shen, Yingqi Hua, Zhengdong Cai
BACKGROUND: Complete resection of pelvic bone tumors, especially recurrent and metastatic ones, is often impossible to achieve using conventional surgery. This study aimed to assess the benefits and adverse effects of computed tomography (CT)-guided radioiodine ((125)I) brachytherapy for inoperable recurrent and metastatic bone tumors of the pelvis. METHODS: This was a retrospective study of 22 patients with confirmed pelvic bone tumors (10 females and 12 males; 15-84 years; 21 with primary pelvic tumor and one with pelvic metastasis)...
November 25, 2016: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27881018/a-different-prognostic-value-of-brafv600e-mutation-positivity-in-different-age-groups-of-patients-with-papillary-thyroid-cancer
#6
E Takacsova, R Kralik, I Waczulikova, K Zavodna, J Kausitz
The aim of retrospective single-center study was to assess the prognostic value of BRAFV600E mutation positivity (BRAFV600E+) on disease persistence/recurrence in patients with papillary thyroid cancer (PTC). A total of 199 patients having had initial surgery with neck dissection in our hospital between 6/2009-6/2012 were included in the cohort. Excluded were patients with unifocal microcarcinoma ≤1cm. BRAFV600E mutation was tested from formalin-fixed paraffin-embedded surgicaly removed tumors. All included patients were postoperatively treated with radioiodine...
November 24, 2016: Neoplasma
https://www.readbyqxmd.com/read/27867395/radioactive-iodine-administration-is-associated-with-persistent-related-symptoms-in-patients-with-differentiated-thyroid-cancer
#7
Pablo Florenzano, Francisco J Guarda, Rodrigo Jaimovich, Nicolás Droppelmann, Hernán González, José M Domínguez
Context. Radioiodine (RAI) administration has adverse effects in patients treated for thyroid cancer (DTC), but there is scarce information regarding their intensity and duration. Objective. To evaluate frequency and intensity of early and late RAI-related symptoms in patients with DTC. Design. Observational prospective study. Patients. DTC patients who underwent thyroidectomy, with or without RAI. Measurements. Patients answered 2 surveys: (1) from 0 to 6 months and (2) between 6 and 18 months after initial treatment...
2016: International Journal of Endocrinology
https://www.readbyqxmd.com/read/27856921/lenvatinib-a-multikinase-inhibitor-for-radioiodine-refractory-differentiated-thyroid-cancer
#8
REVIEW
Yvonne Hewett, Subash Ghimire, Bilal Farooqi, Binay K Shah
Lenvatinib, an oral multikinase inhibitor, was approved by the US Food and Drug Administration in February 2015. In a pivotal phase III study of 392 patients with progressive radioiodine-refractory thyroid cancer, the overall response rate of patients receiving lenvatinib was 64.8%, with complete response in four patients. The median progression-free survival was 18.3 months in the lenvatinib arm versus 3.6 months in patients receiving placebo. Median overall survival was not reached in either arm. Lenvatinib is a promising new treatment for patients with radioiodine (iodine-131)-refractory differentiated thyroid cancer...
November 17, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27853063/successful-re-administration-of-low-dose-of-methimazole-mmi-in-graves-disease-patients-who-experienced-allergic-cutaneous-reactions-to-mmi-at-initial-treatment-and-had-received-long-term-propylthiouracil-ptu
#9
Sumihisa Kubota
Objective When patients with Graves' disease show severe allergic cutaneous reactions, physicians often suggest that they undergo radioiodine therapy instead of receiving propylthiouracil (PTU), another antithyroid drug, because anti-neutrophil cytoplasmic antibody (ANCA) -related vasculitis can occur with PTU, especially with long-term use. However, some patients refuse radioiodine therapy and chose PTU. Sometimes PTU treatment may be prolonged. Since the frequency of adverse effects of methimazole (MMI) is dose-related, there is a possibility that we can re-administer a low dose without adverse effects to patients well-controlled with PTU who once experienced an allergic reaction to MMI...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27848197/12-month-efficacy-of-a-single-radiofrequency-ablation-on-autonomously-functioning-thyroid-nodules
#10
Stella Bernardi, Fulvio Stacul, Andrea Michelli, Fabiola Giudici, Giulia Zuolo, Nicolò de Manzini, Chiara Dobrinja, Fabrizio Zanconati, Bruno Fabris
PURPOSE: Radiofrequency ablation has been advocated as an alternative to radioiodine and/or surgery for the treatment of autonomously functioning benign thyroid nodules. However, only a few studies have measured radiofrequency ablation efficacy on autonomously functioning benign thyroid nodules. The aim of this work was to evaluate the 12-month efficacy of a single session of radiofrequency ablation (performed with the moving shot technique) on solitary autonomously functioning benign thyroid nodules...
November 15, 2016: Endocrine
https://www.readbyqxmd.com/read/27845971/the-follicular-variant-of-papillary-thyroid-cancer-and-noninvasive-follicular-thyroid-neoplasm-with-papillary-like-nuclear-features-niftp
#11
Joseph Scharpf, Dipti Kamani, Peter M Sadow, Gregory W Randolph
PURPOSE OF REVIEW: Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is a new terminology proposed for encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC). Recently, thyroid cancer incidence has increased dramatically, without affecting related mortality rate. This increase is widely attributed to the intensified surveillance leading to a substantial increase in the diagnosis of small classic papillary thyroid cancers and EFVPTCs...
January 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/27831763/thyroid-patient-salivary-radioiodine-transit-and-dysfunction-assessment-using-chewing-gums
#12
Demetrios Okkalides
Radiation-induced salivary gland dysfunction is the most frequent side-effect of I-131 thyroid therapy. Here, a novel saliva sampling method with ordinary chewing gums administered to the patients at appropriate time intervals post-treatment (TIPT) was used to relate this effect to chewing gum saliva activity (CGSA) content. Saliva samples were acquired after the oral administration of prescribed I-131 activity (radioactivity administered [RA]) to 19 differentiated thyroid cancer (DTC) and 16 hyperthyroidism patients of the radioisotope unit (RIU) during 2014 and 2015...
November 2016: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/27824324/no-adverse-effects-after-radioiodine-treatment-at-3-weeks-of-pregnancy
#13
Matea Radacic-Aumiler, Iva Kraljickovic, Viktorija Edeljic-Turk, Ksenija Makar-Ausperger, Robert Likic, Iveta Simic
Radioactive iodine is used for the treatment of hyperthyroidism. Because it accumulates in the fetal thyroid, its administration during pregnancy may cause severe and potentially irreversible hypothyroidism in neonates, with consequent mental retardation, and it is contraindicated during the whole pregnancy. We present a case of a pregnant woman inadvertently treated with 1 mCi (37 MBq) of I in the earliest period of pregnancy and subsequently gave birth to a male infant without signs or symptoms of hypothyroidism or any other damage...
December 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27819764/combination-of-molecular-adsorbent-recirculating-system-and-radioiodine-for-the-treatment-of-concurrent-hyperthyroidism-and-severe-liver-dysfunction-a-retrospective-cohort-study
#14
Qing Zhang, Yanxing Guan, Tianxin Xiang, Shaozheng Liu, Qingjie Chen, Qing Zhang
OBJECTIVE: The treatment of hyperthyroidism associated severe liver dysfunction is a clinical challenge, and there haven't been an unified cognize up to now. The objective of this study was to assess the efficacy and safety of (131)I in combination with a molecular adsorbent recirculating system (MARS) for the treatment of hyperthyroidism complicated by severe liver dysfunction (LD). METHODS: A total of 116 hyperthyroidism patients with concomitant LD who received MARS treatment were studied retrospectively...
November 7, 2016: Endocrine Practice
https://www.readbyqxmd.com/read/27817859/-lenvatinib-in-radioiodine-refractory-thyroid-carcinomas
#15
Christelle de la Fouchardiere
Differentiated thyroid cancers are usually cured by an appropriate surgery and a radioiodine remnant ablation. If metastases occur, successive radioiodine administrations and/or local treatments can be provided. Nevertheless, some patients will be, or become refractory to radioiodine. In case of significant and rapid progression of metastatic lesions, they will be candidate to kinase inhibitor treatments. Two agents are now approved in this situation: sorafenib and lenvatinib. Lenvatinib (Lenvima(®)) is a tyrosine kinase inhibitor (TKI) targeting the VEGFR1-3, FGFR 1-4, PDGFR-α, RET and c-kit...
November 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27813128/preparation-and-preclinical-evaluation-of-131-i-trastuzumab-for-breast-cancer
#16
Mythili Kameswaran, Vikram Gota, Rajwardhan Ambade, Sudeep Gupta, Ashutosh Dash
Trastuzumab that targets the human epidermal growth factor receptor type 2 (HER2) is known to benefit patients with HER2+ metastatic breast cancer. The objective was to explore the potential of (131) I-trastuzumab for treatment of breast cancers. Radioiodination of trastuzumab was carried out by chloramine-T method, purified by using PD-10 column, and characterized by size exclusion high-performance liquid chromatography on a gel column. In vitro studies were carried out in HER2+ cells to determine the specificity of the radioimmunoconjugate...
November 4, 2016: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/27802204/knockdown-of-s100a4-blocks-growth-and-metastasis-of-anaplastic-thyroid-cancer-cells-in-vitro-and-in-vivo
#17
Kejun Zhang, Meiqin Yu, Fengyun Hao, Anbing Dong, Dong Chen
Anaplastic thyroid cancer (ATC) is a locally aggressive type of thyroid tumor with high rate of distant metastases. It is often incurable because it does not respond to radioiodine, radiotherapy, or chemotherapy. With conventional treatment, the median survival is about 6 months; therefore, new treatment options are needed. S100A4 is a calcium-binding protein related to the metastatic potential of carcinoma. Previous study has found S100A4 was overexpressed in human papillary thyroid carcinomas (PTC) tissues, and overexpression of S100A4 is associated with thyroid tumour invasion and metastasis...
September 26, 2016: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/27801741/extrathyroidal-radioiodine-accumulation-in-a-fibroadenoma-of-the-breast
#18
Myoung Hyoun Kim, Hun Soo Kim, Soon-Ah Park
A 45-year-old woman with a differentiated thyroid carcinoma received adjuvant radioiodine therapy following total thyroidectomy and left modified radical neck dissection. A posttherapy planar radioiodine scan showed multifocal uptake in the thyroid bed and left chest. SPECT/CT revealed a fibroadenoma in the left breast. Six months later, an I scan showed no iodine avidity in the breast fibroadenoma, whereas ultrasonography showed no significant change in the size of the fibroadenoma. Altered radioiodine uptake of a breast fibroadenoma can be observed on follow-up scans after cytotoxic radioiodide treatment in patients with differentiated thyroid carcinoma...
October 31, 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27799794/lenvatinib-and-other-tyrosine-kinase-inhibitors-for-the-treatment-of-radioiodine-refractory-advanced-and-progressive-thyroid-cancer
#19
REVIEW
Loredana Lorusso, Letizia Pieruzzi, Agnese Biagini, Elena Sabini, Laura Valerio, Carlotta Giani, Paolo Passannanti, Benedetta Pontillo-Contillo, Valentina Battaglia, Salvatore Mazzeo, Eleonora Molinaro, Rossella Elisei
Lenvatinib is a small oral molecule able to inhibit three of the extracellular and intracellular molecules involved in the modulation of angiogenesis and lymphangiogenesis: vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, and platelet-derived growth factor receptor alpha. Since it is also able to inhibit the REarranged during Transfection oncogene and the protooncogene c-KIT, this drug can also be used to control tumor cell proliferation. The maximum tolerated dose, as demonstrated in Phase I studies, is 25 mg daily...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27764045/evaluation-of-prognostic-factors-associated-with-differentiated-thyroid-carcinoma-with-pulmonary-metastasis
#20
Mohsen Qutbi, Babak Shafeie, Mahasti Amoui, Faraj Tabeie, Zahra Azizmohammadi, Ali Mahmoud-Pashazadeh, Hamid Javadi, Majid Assadi, Isa Neshandar Asli
BACKGROUND: Because one of the major sites for metastasis of thyroid cancers is the lung, studying the pattern of pulmonary metastasis may provide useful information for the effective treatment of these patients. In this study, by assessing the metastasis pattern, we aimed to identify the factors that may affect prognosis and response to treatment in patients with differentiated thyroid carcinoma (DTC) with pulmonary metastasis. METHODS: This retrospective study included 75 patients with DTC with pulmonary metastasis who were referred to our nuclear medicine section over a period of 10 years...
October 18, 2016: Clinical Nuclear Medicine
keyword
keyword
20184
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"